Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

TEXAS CARDIAC ARRHYTHMIA RESEARCH FOUNDATION

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Safety and Efficacy of Pulmonary Vein Isolation Using Pulsed-field Ablation (PFA) Combined with Either PFA-based Left Atrial Posterior Wall Isolation or Vein of Marshall Ethanol Ablation in Patients with Persistent Atrial Fibrillation

Not yet recruiting

Conditions: Atrial Fibrillation (AF)

First Posted Date: 2025-03-17

Last Posted Date: 2025-03-17

Lead Sponsor: Texas Cardiac Arrhythmia Research Foundation

Target Recruit Count: 162

Registration Number: NCT06878924

Safety and Efficacy of Pulsed-field Ablation for Atrial Fibrillation in High Versus Low-volume Ablation Centers (SAFFICIENT)

Terminated

Conditions: Atrial Fibrillation

First Posted Date: 2024-07-05

Last Posted Date: 2025-05-28

Lead Sponsor: Texas Cardiac Arrhythmia Research Foundation

Target Recruit Count: 75

Registration Number: NCT06488820

Locations: 🇺🇸
Texas Cardiac Arrhythmia, Austin, Texas, United States

Post-ablation Alcohol Impacts Arrhythmia Recurrence, Quality of Life and Cognition in AF

Not Applicable

Not yet recruiting

Conditions: Atrial Fibrillation

Interventions: Behavioral: Study arm

First Posted Date: 2022-08-22

Last Posted Date: 2022-08-22

Lead Sponsor: Texas Cardiac Arrhythmia Research Foundation

Target Recruit Count: 130

Registration Number: NCT05510167

Natural History of COVID-19-Related Atrial Fibrillation

Not Applicable

Conditions: COVID-19
Atrial Fibrillation New Onset

Interventions: Device: ILR, PMK, ICD

First Posted Date: 2021-04-05

Last Posted Date: 2021-11-23

Lead Sponsor: Texas Cardiac Arrhythmia Research Foundation

Target Recruit Count: 200

Registration Number: NCT04830774

Locations: 🇺🇸
Kansas City Heart Rhythm Institute, Overland Park, Kansas City, Kansas, United States
🇺🇸
Texas Cardiac Arrhythmia Institute, Austin, Texas, United States
🇧🇪
Vrije Universiteit Brussel, Brussel, Belgium

and more 9 locations

Immune Response Following COVID-19 Vaccination

Conditions: IgM and IgG in Blood

First Posted Date: 2021-02-03

Last Posted Date: 2021-02-03

Lead Sponsor: Texas Cardiac Arrhythmia Research Foundation

Target Recruit Count: 500

Registration Number: NCT04736524

Locations: 🇺🇸
Texas Cardiac arrhythmia Institute, St. David's Hospital, Austin, Texas, United States

RF Applications for Residual LAA Leaks

Not Applicable

Conditions: Left Atrial Appendage Thrombosis
Atrial Fibrillation
Stroke, Ischemic

Interventions: Procedure: Radiofrequency Energy Applications

First Posted Date: 2021-01-27

Last Posted Date: 2021-02-11

Lead Sponsor: Texas Cardiac Arrhythmia Research Foundation

Target Recruit Count: 100

Registration Number: NCT04726943

Locations: 🇺🇸
Kansas City Heart Rhythm Institute, Overland Park, Kansas, United States
🇺🇸
St. David's Medical Center, Austin, Texas, United States

Genetic Mechanisms Underlying SARS-CoV-2 Infection and the Impact of COVID-19 on Cognitive Function

Conditions: Covid19

Interventions: Genetic: Whole exome sequencing

First Posted Date: 2020-08-10

Last Posted Date: 2020-08-27

Lead Sponsor: Texas Cardiac Arrhythmia Research Foundation

Target Recruit Count: 60

Registration Number: NCT04506229

Locations: 🇺🇸
Texas Cardiac Arrhythmia Institute, Austin, Texas, United States

Efficacy of Different Anti-Thrombotic Strategies on Device-Related Thrombosis Prevention After Percutaneous Left Atrial Appendage Occlusion

Phase 4

Conditions: Device-Related Thrombosis
Left Atrial Appendage Occlusion
Atrial Fibrillation

Interventions: Drug: Genetic-Tailored AntiThrombotic Strategy
Drug: Half-Dose of novel OAC
Drug: ASA plus Clopidogrel

First Posted Date: 2020-08-06

Last Posted Date: 2020-08-07

Lead Sponsor: Texas Cardiac Arrhythmia Research Foundation

Target Recruit Count: 360

Registration Number: NCT04502017

Locations: 🇺🇸
St. David's Medical Center, Austin, Texas, United States

Prophylactic Benefit of Hydroxychloroquine in COVID-19 Cases With Mild to Moderate Symptoms and in Healthcare Workers With High Exposure Risk

Not Applicable

Withdrawn

Conditions: COVID-19

Interventions: Drug: Hydroxychloroquine Sulfate

First Posted Date: 2020-05-01

Last Posted Date: 2020-06-04

Lead Sponsor: Texas Cardiac Arrhythmia Research Foundation

Registration Number: NCT04371926

Comparison of the Efficacy of Rapid Tests to Identify COVID-19 Infection (CATCh COVID-19)

Phase 1

Conditions: COVID-19

Interventions: Diagnostic Test: diagnostic tests for COVID-19 infection

First Posted Date: 2020-05-01

Last Posted Date: 2020-08-11

Lead Sponsor: Texas Cardiac Arrhythmia Research Foundation

Target Recruit Count: 100

Registration Number: NCT04372004

Locations: 🇺🇸
Texas Cardiac Arrhythmia Institute, Austin, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy